MALT Lymphoma Trial Fails to Establish Best Frontline Therapy

According to published results of the IESLG-19 trial, adding rituximab to chlorambucil in patients with mucosa-associated lymphoid tissue (MALT) lymphoma did not improve overall survival, despite demonstrating reasonable response rates.

This is a disappointment since the IESLG-19 trial (Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma) was initially launched in an effort to lead to a consensus regarding front-line therapy in MALT lymphoma patients by comparing chlorambucil alone versus chlorambucil plus rituximab in patients not previously given any systemic therapy.

About the Trial

The trial positioned 113 patients in the chlorambucil arm and 114 patients in the combination arm. A third arm was eventually conceived that consisted solely of rituximab, but these findings relate only to the first two arms.

With a median follow-up duration of 62 months, event-free survival (EFS) was 50 percent in the monotherapy arm and 68 percent in the combination arm. Overall response rates were 87 percent for the monotherapy arm and 90 percent for the combination arm. Patients in the combination arm had a higher complete remission rate (78 percent vs 65 percent). A five-year overall survival rate of 89 percent was reported in both arms.

Researchers concluded, "Both treatments were active; the better response rate and EFS obtained with the addition of rituximab did not translate into improved OS."

Source: JCO

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...